Apredica Acquired by Cyprotex
Watertown, MA-based Apredica, a company that does preclinical toxicology assessments of drug candidates, is being acquired by U.K.-based contract research firm Cyprotex for £2.68 million in cash and stock. Katya Tsaioun, the co-founder and CEO of Apredica, will become chief scientific officer of the merged company. Cyprotex says all of Apredica’s employees will remain with the business, and that the two companies have little overlap in their customers. Apredica was founded in 2006 and says it has 173 customers, most of them in the U.S.